指南与共识真菌感染

ESCMID-ECMM指南:新生儿和儿童侵袭性曲霉病的诊断与管理

ESCMID-ECMM guideline: diagnosis and management of invasive aspergillosis in neonates and children.
指南 / 共识 · Clin Microbiol Infect · 2019-05-31

欧洲临床微生物学与感染病学会(ESCMID)和欧洲医学真菌学联盟(ECMM)针对新生儿和儿童侵袭性曲霉病(IA)制定儿科特异性指南。指南工作组通过文献综述和证据分级,围绕流行病学、抗真菌预防获益人群、诊断方法、可用抗真菌药物、唑类治疗药物监测及管理策略提出推荐,旨在促进高危或确诊IA患儿的最佳管理。

要点

  • 儿童与成人IA临床表现相似,但流行病学、基础疾病和诊断工具效用存在差异。
  • 指南涵盖新生儿和儿童IA的抗真菌预防、诊断、治疗及唑类治疗药物监测。
  • 推荐基于文献综述与证据分级,由ESCMID-ECMM-ERS工作组儿科亚组制定。

核心结论

  • 该指南为新生儿和儿童IA的诊断、预防和治疗提供儿科特异性推荐,以促进最佳管理。

研究设计与样本

  • 由ESCMID-ECMM-ERS曲霉病指南工作组的儿科亚组进行文献综述与讨论,并对可用证据质量进行分级。

关键数值与推荐

  • 指南涉及儿童与成人IA在流行病学、基础条件、新诊断工具效用、抗真菌药物药理及3期临床试验证据方面的差异。
  • 指南提出的问题包括新生儿和儿童IA的流行病学、哪些患儿可从抗真菌预防中获益、如何诊断、可用抗真菌药物、预防与治疗药物选择、唑类治疗药物监测的作用及适合儿科患者的管理策略。

临床怎么用

  • 临床可依据该指南对新生儿和儿童IA进行诊断、预防和治疗决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

SCOPE: Presenting symptoms, distributions and patterns of diseases and vulnerability to invasive aspergillosis (IA) are similar between children and adults. However, differences exist in the epidemiology and underlying conditions, the usefulness of newer diagnostic tools, the pharmacology of antifungal agents and in the evidence from interventional phase 3 clinical trials. Therefore, the European Society for Clinical Microbiology and Infectious Diseases (ESCMID) and the European Confederation of Medical Mycology (ECMM) have developed a paediatric-specific guideline for the diagnosis and management of IA in neonates and children. METHODS: Review and discussion of the scientific literature and grading of the available quality of evidence was performed by the paediatric subgroup of the ESCMID-ECMM-European Respiratory Society (ERS) Aspergillus disease guideline working group, which was assigned the mandate for the development of neonatal- and paediatric-specific recommendations. QUESTIONS: Questions addressed by the guideline included the epidemiology of IA in neonates and children; which paediatric patients may benefit from antifungal prophylaxis; how to diagnose IA in neonates and children; which antifungal agents are available for use in neonates and children; which antifungal agents are suitable for prophylaxis and treatment of IA in neonates and children; what is the role of therapeutic drug monitoring of azole antifungals; and which management strategies are suitable to be used in paediatric patients. This guideline provides recommendations for the diagnosis, prevention and treatment of IA in the paediatric population, including neonates. The aim of this guideline is to facilitate optimal management of neonates and children at risk for or diagnosed with IA.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Warris A, Lehrnbecher T, Roilides E, et al. ESCMID-ECMM guideline: diagnosis and management of invasive aspergillosis in neonates and children. Clin Microbiol Infect. 2019. PMID: 31158517. doi:10.1016/j.cmi.2019.05.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。